All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Continued Emergence of Targeted Therapies Reinforces Need for Frequent Genetic Testing in NSCLC

August 25th 2022

Although the efficacy of targeted agents and outcomes for patients with genetic mutations can vary, the availability of these treatments adds to the need for genetic testing across all patients with non–small cell lung cancer.

Olaparib Approved in Japan for BRCA-Mutated, HER2-Negative, High-Risk Early Breast Cancer

August 25th 2022

The Japanese Ministry of Health, Labor, and Welfare has approved olaparib as an adjuvant treatment for patients with BRCA-mutated, HER2-negative, high-risk early breast cancer.

FDA Approval Sought for Lifileucel in Advanced Melanoma

August 25th 2022

A rolling biologics license application has been submitted to the FDA seeking the approval of lifileucel in patients with advanced melanoma who progressed on or after previous anti–PD-1/PD-L1 therapy, and if BRAF mutation positive, also previous BRAF or BRAF/MEK inhibitor therapy.

Allina Health Cancer Institute 2022 Symposium reimagines cancer care

August 25th 2022

Allina Health Cancer Institute is excited to offer its second annual Oncology Symposium on Friday, Sept. 23, 2022. The symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.

Fixed-Duration Ibrutinib Plus Venetoclax Wins EU Approval in Previously Untreated CLL

August 25th 2022

The European Commission has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia.

Larotrectinib Maintains Long-Term Efficacy in Advanced GI Cancers Harboring NTRK Fusions

August 25th 2022

Larotrectinib produced durable responses in patients with NTRK fusion–positive locally advanced or metastatic gastrointestinal cancer, particularly in those with colorectal cancer.

Talimogene Laherparepvec Plus Pembrolizumab Misses Mark in Advanced Melanoma

August 25th 2022

The addition of talimogene laherparepvec to pembrolizumab did not significantly improve progression-free survival or overall survival over pembrolizumab alone in patients with advanced melanoma.

Acalabrutinib With or Without Obinutuzumab Maintains Long-Term Survival Benefit in Untreated CLL

August 24th 2022

Jeff P. Sharman, MD, discusses the meaning of the long-term follow-up data from ELEVATE-TN, the efficacy of acalabrutinib regimens in patients with treatment-naïve chronic lymphocytic leukemia with deletion 17p or TP53 mutations, and factors to consider when adding obinutuzumab to acalabrutinib.

FDA Approves Ibrutinib for Pediatric Patients With Chronic GVHD

August 24th 2022

The FDA has approved ibrutinib (Imbruvica) for pediatric patients aged 1 year or older with chronic graft versus host disease following failure of 1 or more lines of systemic therapy.

European Commission Grants Conditional Marketing Authorization to Teclistamab for Multiple Myeloma

August 24th 2022

The European Commission has granted conditional marketing authorization to teclistamab for use as a single agent in adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Atezolizumab Plus Vemurafenib/Cobimetinib Produces Intracranial Activity in BRAF V600–Mutant Melanoma With CNS Metastases

August 24th 2022

The addition of atezolizumab to vemurafenib and cobimetinib produced promising intracranial activity in patients with BRAF V600–mutated advanced melanoma and central nervous system metastases.

Investigators Validate Role of Liquid Biopsy in Predicting Chromosomal Abnormalities in Myeloid Neoplasms

August 24th 2022

Liquid biopsy using targeted next-generation sequencing for early diagnosis and monitoring of patients with myeloid neoplasms is effective and detects chromosomal structural abnormalities.

Luspatercept-ammt Demonstrates Long-Term Efficacy in LR-MDS

August 24th 2022

Luspatercept, a first-in-class erythroidmaturation agent, induced high clinical activity in patients with transfusion-dependent, lower-risk myelodysplastic syndromes and ring sideroblasts who were relapsed/refractory to erythropoietin, according to findings from the phase 2 PACE-MDS study.

European Union Green Lights PD-L1 Companion Diagnostic for Adjuvant Atezolizumab in NSCLC

August 24th 2022

CE label expansion was granted to the Ventana PD-L1 assay for use as a companion diagnostic to identify patients with non–small cell lung cancer who are eligible for treatment with adjuvant atezolizumab.

NCODA and Florida Cancer Specialists & Research Institute Announce New Oncology Stakeholder Education Exchange Program

August 24th 2022

New cancer treatment therapies, technologies and innovations continue to be discovered and approved for use at a rapid pace, creating an education challenge for physicians and other healthcare professionals within the complex oncology landscape.

FDA Place Clinical Hold on Phase 1 Trial Examining FHD-286 in Relapsed/Refractory AML and MDS

August 23rd 2022

The FDA has placed a full clinical hold on a phase 1 dose escalation trial investigating the BRG1/BRM inhibitor FHD-286 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.

Abivertinib Demonstrates Response and Survival Benefits in Pretreated EGFR T790M–Mutant NSCLC

August 23rd 2022

The novel third-generation EGFR inhibitor abivertinib generated a positive overall response rate and overall survival in heavily pretreated Chinese patients with EGFR T790M–mutated non–small cell lung cancer who failed treatment on a first-line EGFR TKI, according to long-term follow-up data from a phase 1/2 trial (NCT02330367).

Maintenance With Niraparib and Ipilimumab Demonstrates PFS Benefit in Pancreatic Cancer

August 23rd 2022

Niraparib plus ipilimumab maintenance therapy elicited encouraging progression-free survival results in patients with advanced pancreatic cancer who achieved a stable response to platinum-based chemotherapy.

Tislelizumab/Chemo Combo Takes Step Toward Chinese Approval for Unresectable ESCC

August 23rd 2022

The China National Medical Products Administration’s Center for Drug Evaluation has accepted for review a supplemental biologics application seeking the approval of tislelizumab plus chemotherapy in the first-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas

August 23rd 2022

The combination of durvalumab and tremelimumab demonstrated positive progression-free survival and overall survival rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas.